SCHEMBL1070035

SCHEMBL1070035

CC(C=O)=CC1C(C(=O)OCc2ccc(Cl)cc2)C1(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.48
L3MBTL1 Q9Y468 3/20 0.48
LMNA P02545 2/20 0.48
ADRA2A P08913 1/20 0.48
CNR1 P21554 1/20 0.48
ATM Q13315 1/20 0.48
CYP1A2 P05177 3/20 0.46
CYP2C19 P33261 3/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2D6 P10635 1/20 0.46
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
NPSR1 Q6W5P4 2/20 0.38
MAPT P10636 1/20 0.38
GAA P10253 3/20 0.38
HTT P42858 1/20 0.38
TSHR P16473 2/20 0.38
MAOA P21397 3/20 0.36
MAOB P27338 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1070031 1.00 TDP1 (0.48) TDP1L3MBTL1LMNAADRA2ACNR1
SCHEMBL1074316 0.89 TDP1 (0.60) TDP1L3MBTL1LMNAADRA2ACNR1
SCHEMBL1072273 0.88 TDP1 (0.61) TDP1L3MBTL1LMNAADRA2ACNR1
SCHEMBL1072269 0.88 TDP1 (0.61) TDP1L3MBTL1LMNAADRA2ACNR1
SCHEMBL1539164 0.86 L3MBTL1 (0.47) TDP1L3MBTL1LMNAADRA2ACNR1
SCHEMBL1073287 0.85 TDP1 (0.48) TDP1L3MBTL1LMNAADRA2ACNR1
SCHEMBL1073018 0.85 TDP1 (0.51) TDP1L3MBTL1LMNAADRA2ACNR1
SCHEMBL1073015 0.85 TDP1 (0.51) TDP1L3MBTL1LMNAADRA2ACNR1
SCHEMBL1073283 0.85 TDP1 (0.48) TDP1L3MBTL1LMNAADRA2ACNR1
SCHEMBL4992217 0.82 TDP1 (0.46) TDP1L3MBTL1LMNAADRA2ACNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797953-B1 PROCESS FOR PRODUCING OXYGENIC COMPOUND SUMITOMO CHEMICAL CO (JP) 2011-01-05 EP disclosed
US-20080064898-A1 Method for Producing Oxygen-Containing Compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-03-13 US disclosed
US-7276622-B2 Method for producing oxygen-containing compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-10-02 US disclosed
EP-1797953-A1 PROCESS FOR PRODUCING OXYGENIC COMPOUND Sumitomo Chemical Company, Limited (JP) 2007-06-20 EP disclosed
US-20060173221-A1 Method for producing oxygen-containing compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-08-03 US disclosed
EP-1609777-A1 METHOD FOR PRODUCING OXYGEN-CONTAINING COMPOUND Sumitomo Chemical Company, Limited (JP) 2005-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064898-A1 Method for Producing Oxygen-Containing Compound AOC2, AOX1, CAT TDP1 4391/4885L3MBTL1 4186/4885LMNA 3622/4885
US-20060173221-A1 Method for producing oxygen-containing compound GPX4, DUOX2, SCO2 TDP1 4530/4885L3MBTL1 1485/4885LMNA 4036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.